Anavex Life Sciences Corp. (FRA:12X1)

Market Cap	337.94M
Revenue (ttm)	n/a
Net Income (ttm)	-39.53M
Shares Out	n/a
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,104
Open	3.804
Previous Close	3.043
Day's Range	3.804 - 3.804
52-Week Range	2.261 - 13.250
Beta	n/a
RSI	41.32
Earnings Date	Nov 25, 2025

About Anavex Life Sciences

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 34
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 12X1

Financial Performance

Financial numbers in USD